CD8+ lymphocytes suppress human immunodeficiency virus 1 replication by secreting type i Interferons

Journal of Interferon and Cytokine Research

Volumn 33, Issue 11, 2013, Pages 632-645

  Killian, M Scott ^a   Teque, Fernando ^a   Walker, Robert L ^b   Meltzer, Paul S ^b   Killian, J Keith ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; BETA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; INTERFERON;

ARTICLE; ASYMPTOMATIC INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; LYMPHOCYTE; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; TARGET CELL; VIRUS REPLICATION; CD8+ T LYMPHOCYTE; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; SECRETION (PROCESS);

CD8-POSITIVE T-LYMPHOCYTES; HIV-1; HUMANS; INTERFERON TYPE I; MALE; VIRUS REPLICATION;

EID: 84887087802     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0067     Document Type: Article

References (65)

1. Barker E, Mackewicz CE, Reyes-Teran G, Sato A, Stranford SA, Fujimura SH, Christopherson C, Chang SY, Levy JA. 1998. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood 92(9):3105-3114.
2. Brandt ER, Linnane AW, Devenish RJ. 1994. Expression of IFN genes in subpopulations of peripheral blood cells. Br J Haematol 86(4):717-725.
3. Brinchmann JE, Gaudernack G, Vartdal F. 1991. In vitro replication of HIV-1 in naturally infected CD4+ T cells is inhibited by rIFN alpha 2 and by a soluble factor secreted by activated CD8+ T cells, but not by rIFN beta, rIFN gamma, or recombinant tumor necrosis factor-Alpha. J Acquir Immune Defic Syndr 4(5):480-488.
4. Castelli JC, Deeks SG, Shiboski S, Levy JA. 2002. Relationship of CD8( + ) T cell noncytotoxic anti-HIV response to CD4( +) T cell number in untreated asymptomatic HIV-infected individuals. Blood 99(11):4225-4227.
5. Chang TL, Mosoian A, Pine R, Klotman ME, Moore JP. 2002. A soluble factor(s) secreted from CD8( + ) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation. J Virol 76(2):569-581.
6. Cocchi F, DeVico AL, Lu W, Popovic M, Latinovic O, Sajadi MM, Redfield RR, Lafferty MK, Galli M, Garzino-Demo A, Gallo RC. 2012. Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of beta chemokines and RNases. Proc Natl Acad Sci U S A 109(14):5411-5416.
7. Copeland KF, McKay PJ, Rosenthal KL. 1995. Suppression of activation of the human immunodeficiency virus long terminal repeat by CD8 + T cells is not lentivirus specific. AIDS Res Hum Retroviruses 11(11):1321-1326.
8. Cordero F, Botta M, Calogero RA. 2007. Microarray data analysis and mining approaches. Brief Funct Genomic Proteomics 6(4):265-281.
9. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. 1983. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibodysecreting cells. J Immunol Methods 65(1-2):109-121.
10. Davenport MP, Petravic J. 2010. CD8 + T cell control of HIV-A known unknown. PLoS Pathog 6(1):e1000728.
11. Deeks SG, Walker BD. 2007. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27(3):406-416.
12. Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. 2003. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4(5):3.
13. Dustin ML, Chakraborty AK, Shaw AS. 2010. Understanding the structure and function of the immunological synapse. Cold Spring Harbor Perspect Biol 2(10):a002311.
14. Geiben-Lynn R, Kursar M, Brown NV, Kerr EL, Luster AD, Walker BD. 2001. Noncytolytic inhibition of X4 virus by bulk CD8( + ) cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by beta-chemokines. J Virol 75(17):8306-8316.
15. Hartshorn KL, Neumeyer D, Vogt MW, Schooley RT, Hirsch MS. 1987. Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro. AIDS Res Hum Retroviruses 3(2):125-133.
16. Ho DD, Hartshorn KL, Rota TR, Andrews CA, Kaplan JC, Schooley RT, Hirsch MS. 1985. Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet 1(8429):602-604.
17. Hoffman AD, Banapour B, Levy JA. 1985. Characterization of the AIDS-Associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology 147(2): 326-335.
18. Hyrcza MD, Kovacs C, Loutfy M, Halpenny R, Heisler L, Yang S, Wilkins O, Ostrowski M, Der SD. 2007. Distinct transcriptional profiles in ex vivo CD4+ and CD8 + T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8 + T cells. J Virol 81(7):3477-3486.
19. Kaimal V, Bardes EE, Tabar SC, Jegga AG, Aronow BJ. 2010. ToppCluster: a multiple gene list feature analyzer for comparative enrichment clustering and network-based dissection of biological systems. Nucleic Acids Res 38(Web Server issue):W96-W102.
20. Killian MS, Fujimura SH, Hecht FM, Levy JA. 2006. Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment. AIDS 20(9): 1247-1252.
21. Killian MS, Johnson C, Teque F, Fujimura S, Levy JA. 2011. Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8 + T cells. J Virol 85(4):1696-1705.
22. Killian MS, Levy JA. 2011. HIV/AIDS: 30 years of progress and future challenges. Eur J Immunol 41(12):3401-3411.
23. Killian MS, Ng S, Mackewicz CE, Levy JA. 2005. A screening assay for detecting CD8( + ) cell non-cytotoxic anti-HIV responses. J Immunol Methods 304(1-2):137-150.
24. Killian MS, Roop J, Ng S, Hecht FM, Levy JA. 2009. CD8 + cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy. J Clin Immunol 29(3): 311-318.
25. Klatt NR, Shudo E, Ortiz AM, Engram JC, Paiardini M, Lawson B, Miller MD, Else J, Pandrea I, Estes JD, Apetrei C, Schmitz JE, Ribeiro RM, Perelson AS, Silvestri G. 2010. CD8 + lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog 6(1):e1000747.
26. Le Borgne S, Fevrier M, Callebaut C, Lee SP, Riviere Y. 2000. CD8( + )-cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription. J Virol 74(10):4456-4464.
27. Leith JG, Copeland KF, McKay PJ, Richards CD, Rosenthal KL. 1997. CD8 + T-cell-mediated suppression of HIV-1 long terminal repeat-driven gene expression is not modulated by the CC chemokines RANTES, macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta. AIDS 11(5): 575-580.
28. Levy JA. 2003. The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol 24(12):628-632.
29. Levy JA, Mackewicz CE, Barker E. 1996. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today 17(5):217-224.
30. Levy-Koenig RE, Golgher RR, Paucker K. 1970. Immunology of interferons. II. Heterospecific activities of human interferons and their neutralization by antibody. J Immunol 104(4):791-797.
31. Liu L, Johnson C, Fujimura S, Teque F, Levy JA. 2011. Transfection optimization for primary human CD8+ cells. J Immunol Methods 372(1-2):22-29.
32. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(- Delta Delta C(T)) method. Methods 25(4):402-408.
33. Mackewicz CE, Barker E, Greco G, Reyes-Teran G, Levy JA. 1997. Do beta-chemokines have clinical relevance in HIV infection? J Clin Invest 100(4):921-930.
34. Mackewicz CE, Blackbourn DJ, Levy JA. 1995. CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci U S A 92(6): 2308-2312.
35. Mackewicz CE, Craik CS, Levy JA. 2003a. The CD8 + cell noncytotoxic anti-HIV response can be blocked by protease inhibitors. Proc Natl Acad Sci U S A 100(6):3433-3438.
36. Mackewicz CE, Ortega HW, Levy JA. 1991. CD8 + cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 87(4):1462-1466.
37. Mackewicz CE, Ortega H, Levy JA. 1994. Effect of cytokines on HIV replication in CD4 + lymphocytes: lack of identity with the CD8+ cell antiviral factor. Cell Immunol 153(2):329-343.
38. Mackewicz CE, Ridha S, Levy JA. 2000. Fas and Fas ligand are not involved in the suppression of HIV replication by CD8 cells. AIDS 14(2):204-205.
39. Mackewicz CE, Wang B, Metkar S, Richey M, Froelich C, Levy JA. 2003b. Lack of the CD8 + cell anti-HIV factor in CD8 + cell granules. Blood 102(1):180-183.
40. Maitra RK, Silverman RH. 1998. Regulation of human immunodeficiency virus replication by 2,5-oligoadenylate-dependent RNase L. J Virol 72(2):1146-1152.
41. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. 1999. Interferon-Alpha activates multiple STAT proteins and upregulates proliferation-Associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 93(6): 1980-1991.
42. Michaelis B, Levy JA. 1989. HIV replication can be blocked by recombinant human interferon beta. AIDS 3(1):27-31.
43. Moll HP, Maier T, Zommer A, Lavoie T, Brostjan C. 2011. The differential activity of interferon-Alpha subtypes is consistent among distinct target genes and cell types. Cytokine 53(1): 52-59.
44. Payvandi F, Amrute S, Fitzgerald-Bocarsly P. 1998. Exogenous and endogenous IL-10 regulate IFN-Alpha production by peripheral blood mononuclear cells in response to viral stimulation. J Immunol 160(12):5861-5868.
45. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka- Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, OLeary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G, Jr., Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC, Jr., Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL, Jr., Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, McLeod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, OConnor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC, 3rd, Olender SA, Ostrowski M, Owen WF, Jr., Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC, 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM, Jr., Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, vant Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330(6010):1551-1557.
46. Pestka S, Krause CD, Walter MR. 2004. Interferons, interferonlike cytokines, and their receptors. Immunol Rev 202:8-32.
47. Rempel H, Sun B, Calosing C, Pillai SK, Pulliam L. 2010. Interferon- alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. AIDS 24(10):1415-1423.
48. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, Shianna KV, Ge D, Gunthard HF, Goldstein DB, Telenti A. 2010. Genome-wide mRNA expression correlates of viral control in CD4 + T-cells from HIV-1-infected individuals. PLoS Pathog 6(2):e1000781.
49. Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ. 2009. INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res 37(Database issue):D852-D857.
50. Samuel CE. 2001. Antiviral actions of interferons. Clin Microbiol Rev 14(4):778-809, table.
51. Sauce D, Larsen M, Fastenackels S, Pauchard M, Ait-Mohand H, Schneider L, Guihot A, Boufassa F, Zaunders J, Iguertsira M, Bailey M, Gorochov G, Duvivier C, Carcelain G, Kelleher AD, Simon A, Meyer L, Costagliola D, Deeks SG, Lambotte O, Autran B, Hunt PW, Katlama C, Appay V. 2011. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 117(19):5142-5151.
52. Sherman BT, Huang da W, Tan Q, Guo Y, Bour S, Liu D, Stephens R, Baseler MW, Lane HC, Lempicki RA. 2007. DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate highthroughput gene functional analysis. BMC Bioinform 8:426
53. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284(5421):1835-1837.
54. Sperber SJ, Gocke DJ, Haberzettl C, Kuk R, Schwartz B, Pestka S. 1992. Anti-HIV-1 activity of recombinant and hybrid species of interferon-Alpha. J Interferon Res 12(5):363-368.
55. Sperber SJ, Hunger SB, Schwartz B, Pestka S. 1993. Anti-rhinoviral activity of recombinant and hybrid species of interferon alpha. Antiviral Res 22(2-3):121-129.
56. Tanabe Y, Nishibori T, Su L, Arduini RM, Baker DP, David M. 2005. Cutting edge: role of STAT1, STAT3, and STAT5 in IFNalpha beta responses in T lymphocytes. J Immunol 174(2): 609-613.
57. Valle MJ, Jordan GW, Haahr S, Merigan TC. 1975. Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons. J Immunol 115(1):230-233.
58. Walker CM, Erickson AL, Hsueh FC, Levy JA. 1991a. Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8 + cells involves a noncytotoxic mechanism. J Virol 65(11):5921-5927.
59. Walker CM, Levy JA. 1989. A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology 66(4):628-630.
60. Walker CM, Moody DJ, Stites DP, Levy JA. 1986. CD8 + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234(4783):1563-1566.
61. Walker CM, Thomson-Honnebier GA, Hsueh FC, Erickson AL, Pan LZ, Levy JA. 1991b. CD8 + T cells from HIV-1-infected individuals inhibit acute infection by human and primate immunodeficiency viruses. Cell Immunol 137(2):420-428.
62. Wong JK, Strain MC, Porrata R, Reay E, Sankaran-Walters S, Ignacio CC, Russell T, Pillai SK, Looney DJ, Dandekar S. 2010. In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PloS Pathog 6(1):e1000748.
63. Yamamoto JK, Barre-Sinoussi F, Bolton V, Pedersen NC, Gardner MB. 1986. Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res 6(2):143-152.
64. Zhang L, YuW, He T, Yu J, Caffrey RE, Dalmasso EA, Fu S, Pham T, Mei J, Ho JJ, Zhang W, Lopez P, Ho DD. 2002. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 298(5595):995-1000.
65. Zhao XX, Liao MJ, Rashidbaigi A. 1998. Inhibitory effect of interleukin-10 on human leukocyte interferon-Alpha production by Sendai virus. Cytokines Cell Mol Ther 4(1): 11-16.